Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.48 |
| ▸ | PLK2 | Q9NYY3 | 18/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 15/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | TAF1 | P21675 | 1/20 | 0.43 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.43 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10320062 | 0.87 | PLK1 (0.61) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL376094 | 0.87 | PLK1 (0.61) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL1527197 | 0.87 | PLK1 (0.61) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL14310496 | 0.86 | PLK1 (0.48) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL4516187 | 0.86 | PLK1 (0.48) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL18261942 | 0.86 | PLK1 (0.48) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL6840311 | 0.85 | PLK1 (0.58) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL12345547 | 0.84 | PLK1 (0.46) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL2028362 | 0.82 | PLK1 (0.55) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL2028361 | 0.82 | PLK1 (0.55) | PLK1PLK2PLK3BRD4TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2436685-B1 | Intermediate products for producing annulated piperazine-2-on derivatives | BOEHRINGER INGELHEIM INT (DE) | 2015-07-01 | — | — | EP | disclosed |
| EP-2436685-B1 | Intermediate products for producing annulated piperazine-2-on derivatives | BOEHRINGER INGELHEIM INT (DE) | 2015-07-01 | — | — | EP | disclosed |
| EP-1819706-B1 | METHOD FOR PRODUCING ANNELATED PIPERAZIN-2-ONE DERIVATIVES AND INTERMEDIATES OF SAID METHOD | BOEHRINGER INGELHEIM INT (DE) | 2012-09-19 | — | — | EP | disclosed |
| EP-1819706-B1 | METHOD FOR PRODUCING ANNELATED PIPERAZIN-2-ONE DERIVATIVES AND INTERMEDIATES OF SAID METHOD | BOEHRINGER INGELHEIM INT (DE) | 2012-09-19 | — | — | EP | disclosed |
| US-RE43115-E1 | Process for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-17 | — | — | US | disclosed |
| US-RE43115-E1 | Process for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-17 | — | — | US | disclosed |
| US-RE43115-E1 | Process for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-17 | — | — | US | disclosed |
| US-7626019-B2 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7626019-B2 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7626019-B2 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-20070213534-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-13 | — | — | US | disclosed |
| US-20070208027-A1 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-06 | — | — | US | disclosed |
| US-20070208027-A1 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-06 | — | — | US | disclosed |
| US-20070208027-A1 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-06 | — | — | US | disclosed |
| EP-1819706-A1 | METHOD FOR PRODUCING ANNELATED PIPERAZIN-2-ONE DERIVATIVES AND INTERMEDIATES OF SAID METHOD | Boehringer Ingelheim International GmbH (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-7238807-B2 | Hydrogenating a nitropyrimidine derivative with hydrogen in the presence of a hydrogenation catalyst, adding a copper, iron or vanadium compound to produce 7,8-dihydro-5H-pteridin-6-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| US-7238807-B2 | Hydrogenating a nitropyrimidine derivative with hydrogen in the presence of a hydrogenation catalyst, adding a copper, iron or vanadium compound to produce 7,8-dihydro-5H-pteridin-6-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| US-7238807-B2 | Hydrogenating a nitropyrimidine derivative with hydrogen in the presence of a hydrogenation catalyst, adding a copper, iron or vanadium compound to produce 7,8-dihydro-5H-pteridin-6-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| US-20060122393-A1 | Process for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | US | disclosed |
| WO-2006058876-A1 | METHOD FOR PRODUCING ANNELATED PIPERAZIN-2-ONE DERIVATIVES AND INTERMEDIATES OF SAID METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213534-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DHFR, DPYD, DHPS | PLK1 693/4885PLK2 271/4885PLK3 905/4885 |
| US-20070208027-A1 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | DHFR, DPYD, DHPS | PLK1 637/4885PLK2 342/4885PLK3 1005/4885 |
| US-20060122393-A1 | Process for the manufacture of fused piperazin-2-one derivatives | DPYD, CYP1B1, DHFR | PLK1 332/4885PLK2 359/4885PLK3 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.